<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991261</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_16_29</org_study_id>
    <nct_id>NCT02991261</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of SPARC001 (Study 2) in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Open-Label, Single-Dose Bioavailability Study of SPARC001in Healthy, Adult Volunteers Under Fed and Fasted Conditions&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the relative bioavailability, safety and
      tolerability of SPARC001 and Reference001 in healthy, adult, male and female subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">April 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>25 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment type I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment type II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocodone-Acetaminophen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference type II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocodone-Acetaminophen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC001 type I</intervention_name>
    <description>Treatment type I</description>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_label>Reference type II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC001 type II</intervention_name>
    <description>Treatment type II</description>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_label>Reference type II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference001 type I</intervention_name>
    <description>Hydrocodone-acetaminophen</description>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_label>Reference type II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference001 type II</intervention_name>
    <description>Hydrocodone Acetaminophen</description>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_label>Reference type II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult, male and female volunteers, 18 to 55 years of age, inclusive, at first Check-In
             Visit

          2. Body mass index (BMI) ≥18 to ≤30 kg/m2 and total body weight &gt;50 kg (110 lbs) at
             Screening

          3. All female subjects must have a negative serum pregnancy test at Screening and at each
             Check-in Visit

          4. Medically healthy on the basis of medical history and physical examination (including
             but not limited to an evaluation of the cardiovascular, gastrointestinal, respiratory
             and central nervous systems), as determined by the Investigator at Screening and each
             Check-In Visit.

        Exclusion Criteria:

          1. Females who are pregnant, lactating, or likely to become pregnant during the study

          2. Life-time history and/or recent evidence of alcohol or drug/substance abuse disorder

          3. Subjects who need to maintain mental alertness throughout the study

          4. Subjects determined by the investigator to have any medical condition that could
             jeopardize their health or prejudice the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 01</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

